Skip to Content

Join the 'Insulin Glargine / lixisenatide' group to help and get support from people like you.

Insulin Glargine / lixisenatide News

Blame Diabetes: Rates of 2 Nerve Conditions on the Rise

Posted 5 days ago by Drugs.com

FRIDAY, July 21, 2017 – Two particular types of nerve damage (neuropathy) have been increasing as more and more people develop diabetes in the United States, an expert says. Autonomic and small fiber neuropathy were once rare conditions. Both occur when small blood vessels supplying the nerves are damaged by diabetes because they don't get enough oxygen and nutrients, said Dr. Divpreet Kaur, a neurologist at Penn State Health Milton S. Hershey Medical Center. Diabetes is one of the main causes of neuropathy, and about 30 million Americans currently have diabetes, Kaur said. More commonly, people with diabetes have nerve damage that causes numbness in the feet and toes. This is called peripheral neuropathy, according to the American Diabetes Association. Autonomic neuropathy affects involuntary bodily functions such as blood pressure, digestion, sexual function, urination, temperature ... Read more

Related support groups: Diabetes, Type 2, Metformin, Peripheral Neuropathy, Insulin, Lantus, Diabetes, Type 1, Diabetic Neuropathy, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Janumet, Diabetic Nerve Damage, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Pre-Diabetes

Early Menopause May Be Tied to Type 2 Diabetes

Posted 7 days ago by Drugs.com

WEDNESDAY, July 19, 2017 – The earlier a woman begins menopause, the greater her risk of developing diabetes, a new study suggests. Following almost 4,000 women in the Netherlands, Dutch researchers found that those who went through menopause before age 40 were almost four times as likely to develop type 2 diabetes as women whose menopause was late – at 55 or older. The average age for menopause in the United States is 51, according to the National Institute on Aging. Overall, the risk of developing diabetes fell 4 percent for each added year before menopause, according to the study. "Early onset of [natural menopause] is an independent marker for [type 2 diabetes] in postmenopausal women," wrote Dr. Taulant Muka and colleagues at Erasmus University Medical Center in Rotterdam. Their results were published July 18 in the journal Diabetologia. The study doesn't show a direct ... Read more

Related support groups: Diabetes, Type 2, Hot Flashes, Menopausal Disorders, Glipizide, Postmenopausal Symptoms, Insulin Resistance, Janumet, Glyburide, Glimepiride, Pre-Diabetes, Atrophic Vaginitis, Amaryl, Perimenopausal Symptoms, Diabetes Mellitus, Prandin, GlipiZIDE XL, Glucotrol, Dyspareunia, ActoPlus Met, Glucotrol XL

Can Folks With Type 2 Diabetes Forgo the Finger Stick?

Posted 11 Jun 2017 by Drugs.com

SATURDAY, June 10, 2017 – People with type 2 diabetes who aren't taking insulin don't necessarily need to check their blood sugar levels, a new study contends. Many of these patients use "finger prick" blood sugar monitors, but "testing blood sugar didn't have any impact on their blood sugar," said study author Dr. Laura Young, an assistant professor of medicine at the University of North Carolina. "The best way to control blood sugar is to take your medication the way your doctor asks you to and to take good care of yourself," she said. "The key is really taking your medications." Monitoring might be helpful when starting a new medication or changing doses, Young said. "But if someone is on insulin, they absolutely need to be tested regularly," she said. Insulin predisposes people to have blood sugar that's too low, a condition called hypoglycemia. Hypoglycemia can cause dizziness and ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Glucophage, Glipizide, Insulin Resistance, Janumet, Glyburide, Invokana, Glimepiride, Amaryl, Diabetes Mellitus, Glucophage XR, Farxiga, GlipiZIDE XL, Jardiance, Glucotrol, ActoPlus Met, Glucotrol XL, Glumetza

Dealing With Diabetes Distress

Posted 16 Feb 2017 by Drugs.com

THURSDAY, Feb. 16, 2017 – People with diabetes have to think about their condition and make treatment decisions constantly – and all that extra work and worry can lead to psychological distress at times. "Diabetes distress" isn't the same as depression, however, diabetes experts note. It's a condition unique to the 24/7 demands that come with diabetes, particularly for people dependent on insulin. "The day you develop diabetes, it's like the universe just handed you a new full-time job that you have to do in addition to whatever else you're doing. It's a special job that has a big impact on the rest of your life. There's no pay and no vacation," said William Polonsky, president of the Behavioral Diabetes Institute in San Diego. Alicia McAuliffe-Fogarty, vice president of lifestyle management at the American Diabetes Association, put it this way: "Diabetes distress is the extra burden ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Diabetes, Type 1, Glipizide, Glucophage, Novolog, Humalog, Insulin Resistance, Janumet, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Glimepiride, Pre-Diabetes, Novolin R, Amaryl

Sanofi Receives FDA Approval of Soliqua 100/33 (insulin glargine and lixisenatide) for the Treatment of Adults with Type 2 Diabetes

Posted 22 Nov 2016 by Drugs.com

PARIS, Nov. 21, 2016 /PRNewswire-USNewswire/ – Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide*. Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection, studied in a Phase 3 program of more than 1,900 patients. In an insulin intensification study, Soliqua 100/33 showed better HbA1c (average blood sugar over time) lowering versus Lantus with a majority of the 736 patients (55% vs. 30%) achieving the American Diabetes Association target of less than 7% at 30 weeks. Patients treated with Soliqua 100/33 experienced similar rates of documented ... Read more

Related support groups: Diabetes, Type 2, Lantus, Insulin Glargine, Soliqua, Adlyxin, Lixisenatide, Insulin Glargine/lixisenatide

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Related Drug Support Groups

Soliqua

Insulin Glargine / lixisenatide Patient Information at Drugs.com